DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

April 17, 2018
DelMar Pharmaceuticals, Inc.

Updates Provided in Two Poster Presentations at Annual Meeting of the American Association for Cancer Research  VANCOUVER, British Columbia and MENLO PARK, Calif., April 17, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company presented a … Continue reading DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

Aequus and Camargo Complete Pre-Investigational New Drug Submission with FDA for Transdermal Anti-Nausea Program

Aequus Pharmaceuticals Inc.

VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) — Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has issued Camargo Pharmaceutical Services, LLC (“Camargo”) 120,111 common shares on April 11, 2018 in connection with the previously … Continue reading Aequus and Camargo Complete Pre-Investigational New Drug Submission with FDA for Transdermal Anti-Nausea Program

Phoenix Molecular Designs Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND

April 16, 2018
Phoenix MD Inc.

PMD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer (TNBC) VANCOUVER, British Columbia and SAN DIEGO, April 16, 2018 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced that it has entered into a collaboration with STA Pharmaceutical Co., Ltd (STA), a WuXi … Continue reading Phoenix Molecular Designs Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND

DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research

DelMar Pharmaceuticals, Inc.

Update on Ongoing MGMT-unmethylated Clinical Trials to be Presented on Tuesday April 17, 2018 – VANCOUVER, British Columbia and MENLO PARK, Calif., April 16, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced four poster presentations being delivered at … Continue reading DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research

Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018

April 12, 2018
Arbutus Biopharma Corporation

Capsid inhibitor with HBV RNA Destabilizer Demonstrate Complementary Efficacy Results Subcutaneous RNAi Agent Demonstrates Durable HBsAg Reduction Following a Single Dose VANCOUVER, British Columbia and WARMINSTER, Pa., April 12, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today made two presentations supporting our drug combination approach at the 53rd Annual International Liver Congress of … Continue reading Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018

Aequus Adds Zepto Capsulotomy System, A Revenue Generating Product, to Commercial Ophthalmology Portfolio

Aequus Pharmaceuticals Inc.

VANCOUVER, BC. April 12, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce it has entered into a commercial agreement with Mynosys Cellular Devices, an ophthalmology focused medical device company based in Fremont, California, (“Mynosys”) for the Canadian distribution, sales and marketing of the Zepto® Precision Pulse … Continue reading Aequus Adds Zepto Capsulotomy System, A Revenue Generating Product, to Commercial Ophthalmology Portfolio

Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases

April 11, 2018
Arbutus Biopharma Corporation

Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platforms Genevant will be led by Executive Chairman Paris Panayiotopoulos, former CEO of ARIAD Pharmaceuticals through its 2017 acquisition by Takeda, who is assembling a team of RNA experts Dr. Bo Rode Hansen, Global … Continue reading Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases

Zucara Therapeutics Secures US$3.9M from the Helmsley Charitable Trust to Advance Diabetes Lead Drug Candidate to Clinical Trials

April 9, 2018

Toronto and Vancouver, Canada, April 9, 2018 – Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), has secured US$3.9 million in non-dilutive funding from The Leona M. and Harry Helmsley Charitable Trust.   As part of the agreement, Helmsley will provide the funding … Continue reading Zucara Therapeutics Secures US$3.9M from the Helmsley Charitable Trust to Advance Diabetes Lead Drug Candidate to Clinical Trials

SignalChem Lifesciences Corp. to Present Data on the Role of its AXL Inhibitor SLC-391 in Promoting Anti-Tumor Activity

April 6, 2018

• AXL expression is up-regulated by transformed cells and the tumor microenvironment; • Up-regulation of AXL elicits an anti-inflammatory effect; • SLC-391 mediates a pro-inflammatory response by promoting a M2 to M1 transition; and • SLC-391 inhibits M2-induced epithelial mesenchymal transition (EMT). VANCOUVER, BRITISH COLUMBIA – April 9, 2018 – SignalChem Lifesciences Corporation (“SLC”) announced … Continue reading SignalChem Lifesciences Corp. to Present Data on the Role of its AXL Inhibitor SLC-391 in Promoting Anti-Tumor Activity

Arbutus to Present HBV Data at 2018 EASL Liver Meeting

April 4, 2018
Arbutus Biopharma Corporation

VANCOUVER, British Columbia and WARMINSTER, Pa., March 28, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of data at the 53rd Annual International Liver Congress of the European Association for the Study of the Liver (EASL) to be held on April 11-15, 2018 at the Paris Porte de Versailles in Paris, France. “Our data to be presented this … Continue reading Arbutus to Present HBV Data at 2018 EASL Liver Meeting